Cutaneous lupus erythematosus is a chronic autoimmune disease with few treatment options and no approved targeted therapies.

Obinutuzumab was superior to placebo for systemic lupus erythematosus in a phase 3 trial, significantly improving SRI-4 response rates.

Johnson & Johnson's nipocalimab has been granted U.S. Food and Drug Administration Fast Track designation as a potential ...

Phase 3 trial data show that obinutuzumab significantly reduces disease activity in very active extrarenal lupus.

New analysis of Gazyva® shows the drug significantly reduces disease activity in adults with systemic lupus erythematosus.

Objective Systemic lupus erythematosus (SLE) is associated with increased susceptibility to infections, including herpes ...

Systemic lupus erythematosus (SLE) is an autoimmune disease, in which the immune system that normally protects the body from invading microbes turns against the body's own cells. Researchers studied ...

A new study published in Lupus Science & Medicine found a new diagnostic and disease activity monitoring biomarker for systemic lupus erythematosus (SLE) which could help understand pathogenesis, ...